Myriad Genetics Performance dei guadagni passati

Il passato criteri di controllo 0/6

Gli utili di Myriad Genetics sono diminuiti a un tasso medio annuo di -15.6%, mentre il settore Biotechs ha visto gli utili crescere a un tasso medio annuo di 19.1%. I ricavi sono cresciuti crescere a un tasso medio annuo di 2%.

Informazioni chiave

-15.6%

Tasso di crescita degli utili

-11.8%

Tasso di crescita dell'EPS

Biotechs Crescita del settore	17.0%
Tasso di crescita dei ricavi	2.0%
Rendimento del capitale proprio	-15.9%
Margine netto	-14.1%
Ultimo aggiornamento sui guadagni	30 Sep 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

Myriad Genetics, Inc. (NASDAQ:MYGN) Just Reported Earnings, And Analysts Cut Their Target Price

Nov 13

Is Myriad Genetics (NASDAQ:MYGN) A Risky Investment?

Nov 02

Why Investors Shouldn't Be Surprised By Myriad Genetics, Inc.'s (NASDAQ:MYGN) 33% Share Price Plunge

Nov 02

Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

May 11

Analysts Have Made A Financial Statement On Myriad Genetics, Inc.'s (NASDAQ:MYGN) First-Quarter Report

May 09

Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?

Mar 28

An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 37% Undervalued

Feb 02

Myriad Genetics' Strategic Growth Fuels Bullish Outlook

Jan 31

Revenues Working Against Myriad Genetics, Inc.'s (NASDAQ:MYGN) Share Price

Dec 18

Is Myriad Genetics (NASDAQ:MYGN) Using Debt Sensibly?

Aug 07

Calculating The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN)

Apr 13

Ripartizione dei ricavi e delle spese

Come Myriad Genetics guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

NasdaqGS:MYGN Ricavi, spese e utili (USD Millions )
Data	Ricavi	Guadagni	Spese G+A	Spese di R&S
30 Sep 24	824	-116	563	102
30 Jun 24	802	-155	560	98
31 Mar 24	774	-235	562	91
31 Dec 23	753	-263	567	89
30 Sep 23	734	-274	587	91
30 Jun 23	699	-248	581	88
31 Mar 23	695	-146	551	87
31 Dec 22	678	-112	527	85
30 Sep 22	661	-77	444	83
30 Jun 22	672	-18	494	81
31 Mar 22	682	-8	513	80
31 Dec 21	691	-27	538	82
30 Sep 21	684	-57	599	80
30 Jun 21	662	-97	542	78
31 Mar 21	566	-148	514	76
31 Dec 20	557	-224	501	73
30 Sep 20	598	-194	499	74
30 Jun 20	639	-199	507	77
31 Mar 20	761	-148	539	81
31 Dec 19	813	-26	546	83
30 Sep 19	835	-15	547	86
30 Jun 19	851	5	557	86
31 Mar 19	830	23	512	83
31 Dec 18	796	26	479	80
30 Sep 18	767	54	451	74
30 Jun 18	744	133	435	71
31 Mar 18	749	130	444	72
31 Dec 17	763	126	459	71
30 Sep 17	771	101	472	73
30 Jun 17	729	17	440	74
31 Mar 17	757	32	446	75
31 Dec 16	751	63	414	75
30 Sep 16	748	94	385	73
30 Jun 16	741	117	359	71
31 Mar 16	757	121	349	70
31 Dec 15	747	108	349	69
30 Sep 15	738	95	351	70
30 Jun 15	723	80	366	76
31 Mar 15	722	95	354	77
31 Dec 14	725	110	350	74
30 Sep 14	745	137	335	73
30 Jun 14	778	176	327	68
31 Mar 14	764	187	314	60
31 Dec 13	737	188	291	61

Guadagni di qualità: MYGN al momento non è redditizia.

Margine di profitto in crescita: MYGN al momento non è redditizia.

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: MYGN non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 15.6% all'anno.

Accelerare la crescita: Impossibile confrontare la crescita degli utili di MYGN nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia

Guadagni vs Settore: MYGN non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Biotechs ( 16.6% ).

Rendimento del capitale proprio

ROE elevato: MYGN ha un Return on Equity negativo ( -15.85% ), in quanto al momento non è redditizio.

Myriad Genetics Performance dei guadagni passati

Il passato criteri di controllo 0/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Myriad Genetics, Inc. Reports Impairment Charges for the Third Quarter Ended September 30, 2024

Myriad Genetics, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Myriad Genetics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Recent updates

Myriad Genetics, Inc. (NASDAQ:MYGN) Just Reported Earnings, And Analysts Cut Their Target Price

Price target decreased by 11% to US$26.69

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Myriad Genetics, Inc. Reports Impairment Charges for the Third Quarter Ended September 30, 2024

Is Myriad Genetics (NASDAQ:MYGN) A Risky Investment?

Why Investors Shouldn't Be Surprised By Myriad Genetics, Inc.'s (NASDAQ:MYGN) 33% Share Price Plunge

Myriad Genetics, Inc. to Report Q3, 2024 Results on Nov 07, 2024

CEO, President & Director notifies of intention to sell stock

Now 21% undervalued after recent price drop

Myriad Genetics, Inc. Provides Earnings Guidance for the Third Quarter 2024 and Reaffirms Earnings Guidance for the Full-Year 2024

Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 31% Discount?

Myriad Genetics, Inc. to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference

Independent Director recently sold US$271k worth of stock

Independent Director notifies of intention to sell stock

Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking

Insider recently sold US$321k worth of stock

Consensus EPS estimates fall by 25%

Price target increased by 7.6% to US$27.82

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Myriad Genetics, Inc. Raises Earnings Guidance for the Full Year 2024

Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer, Effective September 3, 2024

Myriad Genetics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Is Myriad Genetics (NASDAQ:MYGN) Weighed On By Its Debt Load?

New minor risk - Financial position

Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 33% Discount?

CEO, President & Director recently sold US$5.7m worth of stock

CEO, President & Director notifies of intention to sell stock

Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Analysts Have Made A Financial Statement On Myriad Genetics, Inc.'s (NASDAQ:MYGN) First-Quarter Report

Myriad Genetics, Inc. Reiterates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Myriad Genetics, Inc. to Report Q1, 2024 Results on May 07, 2024

Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?

Consensus EPS estimates upgraded to US$0.93 loss

Price target increased by 8.9% to US$24.50

Myriad Genetics, Inc. Provides Revenue Guidance for the First Quarter 2024

Full year 2023 earnings: EPS misses analyst expectations

Myriad Genetics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 37% Undervalued

Myriad Genetics' Strategic Growth Fuels Bullish Outlook

Myriad Genetics, Inc. Appoints George Daneker as President and Chief Clinical Officer of Oncology, Effective March 18, 2024

Myriad Genetics, Inc. (NasdaqGS:MYGN) agreed to acquire Select assets of Intermountain Precision Genomics.

Myriad Genetics, Inc. Announces Chief Financial Officer Changes

Revenues Working Against Myriad Genetics, Inc.'s (NASDAQ:MYGN) Share Price

Consensus EPS estimates fall by 21%, revenue upgraded

Myriad Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New minor risk - Shareholder dilution

Myriad Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Myriad Genetics, Inc. Provides Financial Guidance for 2023 and 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Executive VP notifies of intention to sell stock

Myriad Genetics, Inc. Appoints Samraat S. Raha as Chief Operating Officer, Effective as of December 11, 2023

Myriad Genetics Appoints Sam Raha as Chief Operating Officer, Effective December 11, 2023

Myriad Genetics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Price target decreased by 8.2% to US$21.67

Bernstein Litowitz Berger & Grossmann LLP Proposes Settlement of Class Action Involving Persons Who Purchased or Acquired Myriad Genetics, Inc. Common Stock

Insufficient new directors

Consensus EPS estimates fall by 52%

Myriad Genetics Announces Enhancements to the Genesight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status

Is Myriad Genetics (NASDAQ:MYGN) Using Debt Sensibly?

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Myriad Genetics, Inc. Provides Earnings Guidance for the Year 2023

Myriad Genetics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Myriad Genetics, Inc. Announces Inclusion of Breast Density to Myrisk(R) with Riskscore(R) Breast Cancer Risk Assessment

Independent Director notifies of intention to sell stock

Myriad Genetics, Inc. Appoints Adam Brufsky as Scientific Advisor

Consensus EPS estimates fall by 27%, revenue upgraded

Myriad Genetics, Inc. Revises Earnings Guidance for the Full Year of 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind